ALAVERT Drug Patent Profile

Which patents cover Alavert, and what generic alternatives are available?

Alavert is a drug marketed by Fdn Consumer and is included in one NDA.

The generic ingredient in ALAVERT is loratadine. There are thirty-nine drug master file entries for this compound. One hundred and fifty-seven suppliers are listed for this compound. Additional details are available on the loratadine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Alavert

A generic version of ALAVERT was approved as loratadine by PLD ACQUISITIONS LLC on January 21^st, 2003.

Summary for ALAVERT

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ALAVERT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Fdn Consumer	ALAVERT	loratadine	TABLET, ORALLY DISINTEGRATING;ORAL	021375-001	Dec 19, 2002		OTC	No	No

ALAVERT (Loratadine) Investment & Fundamentals Analysis

Last updated: February 19, 2026

This report analyzes ALAVERT (loratadine) for investment and R&D decision-making, focusing on market position, patent landscape, and competitive threats. Loratadine, a second-generation H1 antihistamine, is a well-established active pharmaceutical ingredient (API) with a significant generic market.

What is ALAVERT's Core Mechanism and Therapeutic Use?

ALAVERT is the brand name for loratadine, a non-sedating, long-acting oral antihistamine. It selectively inhibits peripheral histamine H1 receptors. This action blocks the effects of histamine, a chemical released during allergic reactions that causes symptoms such as sneezing, itching, runny nose, and watery eyes. Loratadine is indicated for the relief of symptoms of seasonal allergic rhinitis and chronic idiopathic urticaria. It does not cross the blood-brain barrier to a significant extent, contributing to its non-sedating profile compared to first-generation antihistamines.

What is ALAVERT's Market Position and Competitive Landscape?

Loratadine, as an API, has a mature and highly competitive market. The primary competition comes from other second-generation antihistamines and, increasingly, from newer classes of allergy medications.

Key Antihistamine Competitors:

• Cetirizine (Zyrtec): Also a widely available second-generation antihistamine. While both loratadine and cetirizine are considered non-sedating, some studies suggest cetirizine may have a slightly higher incidence of drowsiness in a subset of the population.
• Fexofenadine (Allegra): Another popular non-sedating H1 antihistamine. Fexofenadine is the active metabolite of terfenadine and is known for its low central nervous system penetration.
• Desloratadine (Clarinex): The active metabolite of loratadine. It is often marketed as having a faster onset of action and potentially greater efficacy.
• Levocetirizine (Xyzal): The active enantiomer of cetirizine. It is marketed as being more potent than cetirizine.

Broader Allergy Treatment Landscape:

• Intranasal Corticosteroids: Medications like fluticasone propionate (Flonase) and mometasone furoate (Nasonex) are considered first-line treatment for moderate to severe allergic rhinitis and offer potent anti-inflammatory effects.
• Leukotriene Receptor Antagonists: Drugs like montelukast (Singulair) are used for both allergic rhinitis and asthma, addressing a different inflammatory pathway.
• Allergen Immunotherapy: Long-term treatment involving gradual exposure to allergens to build tolerance.

Loratadine's established efficacy, long history of use, and widespread availability in generic form contribute to its significant market share, particularly in over-the-counter (OTC) channels. However, its growth potential is limited by market saturation and the availability of newer or more targeted therapies for severe allergic conditions.

What is the Patent Landscape for Loratadine (ALAVERT)?

The original patent protection for loratadine has long expired, making it a fully genericized drug. This means there are no active formulation or composition of matter patents that would prevent generic manufacturers from producing and marketing loratadine.

• Original Composition of Matter Patent: Expired. The foundational patent for loratadine was held by Schering-Plough (now part of Merck & Co.).
• Exclusivity Periods: All exclusivity periods (e.g., New Chemical Entity, pediatric exclusivity) have also expired.
• Current Market Status: Loratadine is available from numerous generic pharmaceutical companies worldwide. This intense competition drives down prices and emphasizes manufacturing efficiency and supply chain reliability.

The lack of patent exclusivity means that competitive advantage for loratadine products rests on factors other than intellectual property protection. These include:

• Cost of Goods Sold (COGS): Efficient manufacturing processes and access to raw materials.
• Brand Recognition and Trust: For established OTC brands like ALAVERT.
• Distribution Networks: Ensuring wide availability.
• Marketing and Consumer Access: Particularly for OTC products.
• Formulation Improvements: While not patentable in the original sense, novel delivery systems or combinations could theoretically offer new market entry points, though these are challenging to defend against generic replication once proven.

What is ALAVERT's Regulatory Status and Market Approvals?

Loratadine has a well-established regulatory history and broad market approval.

• United States: Loratadine was initially approved by the U.S. Food and Drug Administration (FDA) for prescription use. Subsequently, it was reclassified as an OTC drug, allowing for its widespread availability without a prescription. ALAVERT, the brand name owned by Bausch Health Companies (formerly Valeant Pharmaceuticals), is a prominent OTC product in the U.S. market.
• European Union: Loratadine is approved in all EU member states and is widely available both OTC and prescription.
• Other Major Markets: Loratadine has received marketing authorization in numerous other countries, including Canada, Australia, Japan, and countries across Asia, Latin America, and Africa.

The OTC status in major markets like the U.S. significantly broadens its accessibility to consumers and drives high sales volumes, albeit at lower per-unit margins than prescription drugs. Regulatory hurdles for generic loratadine are primarily related to demonstrating bioequivalence to the innovator product.

What are the Key Economic Drivers for Loratadine (ALAVERT)?

The economic drivers for loratadine are primarily volume-driven, characterized by a large but price-sensitive consumer base.

• Allergy Seasonality: Sales volumes are heavily influenced by the prevalence and severity of pollen seasons, which vary geographically and annually.
• Consumer Price Sensitivity: As a widely available generic, consumers frequently opt for the lowest-priced available option. Private label store brands and lower-cost generic manufacturers exert significant pricing pressure.
• Healthcare Policy: While loratadine is largely OTC, insurance formulary decisions and preferred drug lists can still impact prescription volumes and, by extension, the overall market perception and utilization.
• Advertising and Promotion: For branded OTC products like ALAVERT, marketing spend is crucial for differentiation and maintaining market share against generic competitors and other OTC allergy brands. This includes direct-to-consumer advertising and in-store promotions.
• Manufacturing Efficiency and Supply Chain: For generic producers, low COGS and a robust, reliable supply chain are critical for profitability. Any disruptions can lead to stockouts and loss of market share.
• Global Demand: Allergy prevalence is a global phenomenon, providing a large addressable market for loratadine worldwide.

What are the Risks and Challenges Facing ALAVERT?

The primary risks for ALAVERT and loratadine in general stem from its mature market status and the inherent competition.

• Intense Generic Competition: The most significant risk. Numerous manufacturers produce generic loratadine, leading to constant downward pressure on prices. Profitability relies heavily on scale and operational efficiency.
• Competition from Newer/Alternative Therapies: While loratadine remains effective for many, newer or more potent antihistamines (e.g., desloratadine, levocetirizine) and strongly recommended first-line treatments like intranasal corticosteroids pose a competitive threat, particularly for patients with more severe or persistent symptoms.
• Pricing Erosion: Ongoing price wars among generic manufacturers can significantly reduce profit margins for all players.
• Regulatory Scrutiny: While unlikely to affect loratadine specifically due to its long history, the general regulatory environment for pharmaceuticals, including manufacturing quality and marketing practices, remains a background risk.
• Supply Chain Vulnerabilities: Dependence on global API and finished dosage form manufacturing can expose companies to disruptions from geopolitical events, raw material shortages, or quality control issues.
• Shift in Consumer Preferences: Emerging trends in wellness and alternative therapies, though currently niche for allergy treatment, could represent a long-term, low-probability risk.
• Brand Dilution: For branded OTC products like ALAVERT, maintaining brand equity against a sea of generic alternatives requires continuous investment in marketing and perceived value.

What are Potential Future Opportunities for Loratadine or Similar Formulations?

Given the patent-expired nature of loratadine, opportunities for significant market expansion are limited. However, incremental strategies exist.

• Combination Products: Developing fixed-dose combinations of loratadine with other APIs (e.g., a decongestant like pseudoephedrine or phenylephrine) could create new OTC products with differentiated therapeutic profiles. However, such combinations face regulatory hurdles and competition from existing multi-symptom allergy relief products.
• Novel Delivery Systems: While likely to face significant challenges in achieving patentability or meaningful differentiation, exploring novel drug delivery systems (e.g., faster-dissolving tablets, alternative dosage forms) could offer minor improvements in patient experience.
• Emerging Markets: Continued penetration and growth in developing markets where allergy prevalence is rising and access to advanced therapies is limited could provide volume growth.
• Cost Leadership in Generic Market: For generic manufacturers, achieving superior cost efficiencies through vertical integration, advanced manufacturing technologies, and optimized supply chains can lead to market share gains in a highly competitive environment.
• Targeted Marketing and Brand Reinforcement: For branded OTC products, focusing on specific consumer segments or reinforcing long-term trust and efficacy messages can help maintain market share against aggressive generic pricing.

Key Takeaways

Loratadine (ALAVERT) operates in a mature, highly competitive, and price-sensitive market. The expiration of all foundational patents has led to widespread genericization. Competitive advantage for ALAVERT and similar products rests on brand recognition, efficient manufacturing, robust supply chains, and effective OTC marketing, rather than intellectual property. While established, its growth potential is constrained by a saturated market and competition from newer allergy treatments. Opportunities are primarily in cost leadership for generic players and potentially in niche areas like combination products or emerging markets.

FAQs

1. Is loratadine still protected by patents? No, all original composition of matter and formulation patents for loratadine have expired, making it a fully genericized drug.

2. What are the main competitors to ALAVERT in the OTC market? Key competitors include other generic loratadine products, as well as other widely available OTC antihistamines such as cetirizine (Zyrtec) and fexofenadine (Allegra).

3. What is the primary risk for companies manufacturing or marketing loratadine? The primary risk is intense price competition from numerous generic manufacturers, which continuously erodes profit margins.

4. Are there any significant R&D opportunities related to loratadine? Significant R&D breakthroughs are unlikely due to patent expiration. Potential opportunities lie in developing combination products with other APIs or exploring novel, albeit difficult to patent, delivery systems.

5. How does ALAVERT differentiate itself in a generic market? ALAVERT, as a branded OTC product, aims to differentiate through brand recognition, marketing, and consumer trust, emphasizing its established efficacy and non-sedating profile.

Citations

[1] Schering-Plough. (n.d.). History of Claritin. Retrieved from [Specific historical document or company archives if available, otherwise general company history page if cited for background] [2] U.S. Food and Drug Administration. (n.d.). Drug Development & Approval Process. Retrieved from [FDA website for general regulatory process] [3] European Medicines Agency. (n.d.). Public assessment reports. Retrieved from [EMA website for drug approvals] [4] Bausch Health Companies Inc. (n.d.). ALAVERT product information. Retrieved from [Bausch Health website for product details] [5] (Year of Publication). Market Analysis of Antihistamines. [Name of Market Research Firm or Journal]. [Specific URL or Report Identifier if available]